Compare Quest Diagnostics Inc (DGX) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.61. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| DGX | VTIP | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | — |
52-Week High | $216.02 | $50.75 |
52-Week Low | $166.42 | $49.39 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
VTIP trades at $49.61, down slightly by 0.06% with a bearish technical signal from moving averages. The ETF focuses on short-term inflation-protected securities, offering investors protection against persistent inflation currently running at 3.8%. Recent institutional activity shows mixed positioning with several firms increasing holdings while others trimmed positions. The overall technical picture remains cautious despite neutral oscillator readings.
VTIP provides inflation hedging with potential 3.8% returns in the current environment, though the Fed's reluctance to cut rates in 2026 presents headwinds. The ETF's short-term TIPS focus reduces duration risk but remains sensitive to inflation expectations and monetary policy shifts. Key risks include interest rate volatility and inflation trajectory uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
